Mavs’ Noel, Jazz’s Sefolosha get 5-game drug bans from NBA | Inquirer Sports

Mavs’ Noel, Jazz’s Sefolosha get 5-game drug bans from NBA

/ 10:08 AM April 04, 2018

FILE – Nerlens Noel #3 of the Dallas Mavericks rebounds against Denzel Valentine #45 of the Chicago Bulls at the United Center on March 2, 2018 in Chicago, Illinois. Jonathan Daniel/Getty Images/AFP

NEW YORK — Dallas Mavericks center Nerlens Noel and Utah Jazz forward Thabo Sefolosha have been suspended five games for violating the NBA’s anti-drug program.

The league announced the suspensions Tuesday. Noel’s ban will cover the final five games of the season for the lottery-bound Mavericks, starting Tuesday night against Portland.

Article continues after this advertisement

Sefolosha had surgery on the MCL in his right knee in January and hasn’t returned. His suspension will begin in the next regular-season or playoff game when he is eligible and physically able to play.

FEATURED STORIES

Noel’s suspension ends a lost season for a player trying to earn a long-term contract after failed negotiations last offseason resulted in him signing the team’s qualifying offer of just $4.1 million for one year.

Noel played just 30 games, with most of the missed time coming after surgery for a torn ligament in his left thumb in December. He averaged 4.4 points and 5.6 rebounds in 16 minutes a game in his fourth season in the league

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: NBA, Nerlens Noel, Thabo Sefolosha

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.